World Journal of Current Medical and Pharmaceutical Research
Content available at www.wjcmpr.com ISSN: 2582-0222

INNOVATIVE NANOMATERIAL-BASED ANALYTICAL TECHNIQUES FOR EARLY DETECTION OF DISEASES: A COMPREHENSIVE REVIEW

Sukumar Reddy Bhuma
Department of Chemistry, Sri Venkateswara University, Tirupati, Andhra Pradesh-517502

Article History
Received on: 19-07-2024
Revised on: 25-07-2024
Accepted on: 07-09-2024

Abstract
Early and accurate disease diagnosis is crucial for improving patient outcomes and reducing healthcare costs. Nanomaterials have emerged as transformative tools in enhancing the sensitivity and specificity of analytical methods for early disease detection. This review explores various nanomaterials, including metallic nanoparticles, carbon-based nanomaterials, quantum dots, and polymeric nanoparticles, and their application in biosensors, immunoassays, molecular imaging, and lab-on-a-chip devices. These advanced materials significantly improve the detection of disease biomarkers at low concentrations, enabling earlier and more accurate diagnosis than traditional methods. Despite the challenges associated with toxicity, reproducibility, and regulatory approval, nanomaterial-based diagnostic methods offer unparalleled potential in revolutionising early disease detection. The review also discusses future directions, highlighting the integration of nanomaterials with technologies like artificial intelligence and the progress toward commercializing nanomaterial-based diagnostic tools. As the field advances, nanomaterials are poised to play a pivotal role in the future of personalised medicine and point-of-care diagnostics.

Keywords: Nanomaterials, Early Disease Diagnosis, Biosensors, Immunoassays, Molecular Imaging, Lab-on-a-Chip, Biomarkers.

***Corresponding Author**
Sukumar Reddy Bhuma

DOI: https://doi.org/10.37022/wjcmpr.v6i2.339

Introduction

Early disease diagnosis is crucial in modern medicine, as it significantly increases the chances of successful treatment and improves patient outcomes. Identifying diseases at an early stage allows for timely intervention, potentially preventing the progression of conditions that could otherwise become life-threatening or result in chronic complications. Moreover, early diagnosis reduces healthcare costs by minimizing the need for extensive treatments and prolonged hospital stays, ultimately benefiting patients and healthcare systems [1].

Nanomaterials have emerged as powerful diagnostic tools due to their unique properties, including high surface area-to-volume ratios, tunable optical and electronic characteristics, and the ability to interact with biological molecules at the nanoscale. These properties make nanomaterials highly sensitive and selective, ideal for detecting minute concentrations of disease-associated biomarkers [2]. For instance, gold nanoparticles exhibit plasmonic properties that can be harnessed for enhanced imaging and detection. At the same time, carbon-based nanomaterials like graphene offer exceptional electrical conductivity, making them suitable for sensitive biosensors [3].

Integrating nanomaterials into analytical methods has revolutionized the field of diagnostics, offering unprecedented sensitivity and specificity. Nanomaterial-based diagnostics can detect disease biomarkers at much lower concentrations than conventional methods, leading to earlier detection and more accurate diagnoses [4]. This integration also facilitates the development of portable, point-of-care diagnostic devices essential for rapid and accessible healthcare delivery, particularly in resource-limited settings. The ongoing research and innovation in this field continue to push the boundaries of what is possible in early disease detection, promising a future where diagnosis is quicker, more accurate, and less invasive [5].

Role of Nanomaterials

Nanomaterials are materials with at least one dimension in the nanometer scale (1-100 nm), exhibiting distinct physical, chemical, and biological properties compared to their bulk counterparts. These properties include a high surface area-to-volume ratio, which enhances their reactivity and interaction with biological molecules. Additionally, nanomaterials can be engineered for specific optical, magnetic, or electrical characteristics, making them versatile tools in various applications, particularly biomedical diagnostics [6].

Nanomaterials significantly improve the performance of analytical methods used in early disease detection by increasing sensitivity, specificity, and speed. For example, gold nanoparticles are employed in colorimetric assays due to their plasmonic solid properties, enabling the detection of low concentrations of disease biomarkers. Carbon-based nanomaterials like graphene enhance the conductivity of biosensors, leading to faster and more accurate detection of target molecules [7]. Moreover, quantum dots provide bright and stable fluorescence, which improves the resolution in imaging techniques, allowing for the early detection of diseases such as cancer. Integrating nanomaterials into these analytical methods makes it possible to detect diseases at their earliest stages, potentially before symptoms even appear, thus facilitating timely and effective treatment [8].

Table 1: Comparison of Different Types of Nanomaterials Used in Early Disease Diagnosis

Nanomaterial Type	Key Properties	Applications	Challenges
Metallic Nanoparticles	High surface area, plasmonic properties	Biosensors, Imaging	Toxicity, cost
Carbon Nanomaterials	High conductivity, biocompatibility	Sensors, Drug delivery	Synthesis complexity, reproducibility
Quantum Dots	Fluorescence, tunable optical properties	Imaging, Fluorescent tagging	Toxicity, stability
Polymeric Nanoparticles	Biodegradability, functionalization	Targeted drug delivery, Biosensors	Complex fabrication, low yield

Scope of the Review

This review concentrates on diverse analytical methods incorporating nanomaterials, highlighting how these advanced materials enhance diagnostic capabilities. The focus is on the various types of nanomaterials, including metallic nanoparticles, carbon-based nanomaterials, quantum dots, and polymeric nanoparticles, and how they are utilised in different analytical techniques such as biosensors, immunoassays, molecular imaging, and lab-on-a-chip devices.

The review emphasises the application of these nanomaterial-based methods in the early diagnosis of a wide range of diseases, including cancer, infectious diseases, cardiovascular disorders, and neurodegenerative conditions. It explores how the enhanced sensitivity and specificity provided by nanomaterials contribute to detecting disease biomarkers at earlier stages, which is crucial for timely intervention and improved patient outcomes. The review also discusses the potential for these methods to be developed into point-of-care diagnostics, further advancing the field of early disease detection.

Types of Nanomaterials Used in Analytical Methods

Nanomaterials are pivotal in enhancing the capabilities of analytical methods for early disease detection due to their unique and tunable properties. Metallic nanoparticles, such as gold and silver, are widely used in biosensing and imaging due to their strong surface plasmon resonance, which enhances signal detection [9]. Carbon-based nanomaterials like graphene and carbon nanotubes offer high electrical conductivity and large surface areas, making them ideal for sensitive electrochemical sensors and bioassays. Polymeric nanoparticles, including dendrimers and liposomes, play a crucial role in targeted drug delivery and diagnostic assays thanks to their biocompatibility and ability to be functionalized with various biomolecules. Quantum dots are valued for their bright, size-tunable fluorescence, useful in multiplexed diagnostic assays and high-resolution imaging. Lastly, magnetic nanoparticles are employed in magnetic resonance imaging (MRI) and magnetic separation techniques, providing high sensitivity and specificity in detecting disease biomarkers. These diverse nanomaterials collectively contribute to advancing analytical methods, enabling earlier and more accurate disease diagnosis [10-14].

Table 2: Types of Nanomaterials Used in Analytical Methods

Nanomaterial Type	Examples	Key Properties	Applications
Metallic Nanoparticles	Gold, Silver, Platinum	High surface plasmon resonance (SPR), conductivity	Biosensing, Imaging (e.g., surface-enhanced Raman scattering, SERS)
Carbon-Based Nanomaterials	Graphene, Carbon Nanotubes, Fullerenes	High electrical conductivity, large surface area	Electrochemical Sensors, Bioassays, Drug delivery
Polymeric Nanoparticles	Dendrimers, Micelles, Liposomes	Biodegradability, functionalization potential	Targeted Drug Delivery, Diagnostic Assays
Quantum Dots	Semiconductor nanocrystals (e.g., CdSe, CdTe)	Bright, stable fluorescence, size-tunable emission	Fluorescent Imaging, Multiplexed Diagnostic Assays
Magnetic Nanoparticles	Iron oxide (Fe_3O_4), Cobalt	Superparamagnetic, magnetic response	Magnetic Resonance Imaging (MRI), Magnetic Separation Techniques

Nanomaterial-Based Analytical Techniques

Nanomaterials have revolutionized analytical techniques by significantly enhancing their sensitivity, specificity, and speed, making them indispensable tools for early disease detection. In biosensors, nanomaterials such as gold nanoparticles, carbon nanotubes, and graphene are used to design highly sensitive platforms that can detect specific biomarkers with exceptional precision [15]. Case studies highlight disease-specific biosensors, such as glucose sensors for diabetes and PSA sensors for prostate cancer, showcasing their potential in real-world applications. Nanomaterials amplify the signal in immunoassays, allowing for the early detection of diseases like cancer and infectious diseases by targeting specific antigens with increased accuracy [16]. Nucleic acid-based detection techniques, such as PCR and qPCR, are enhanced by nanoparticles, which improve the efficiency of these amplification methods, enabling the detection of genetic markers associated with early-stage diseases. Imaging techniques, including MRI, PET, CT, and fluorescence imaging, benefit from nanoparticle enhancements that provide better contrast and resolution, facilitating the early detection of tumours and other pathological changes [17-20]. Finally, lab-on-a-chip devices integrate nanomaterials into microfluidic systems, enabling point-of-care diagnostics that are portable, fast, and capable of early disease detection at the patient's bedside or in resource-limited settings [21].

Table 3: Nanomaterials-based analytical techniques

Analytical Technique	Nanomaterial Used	Key Enhancements	Applications
Biosensors	Gold nanoparticles, Carbon nanotubes, Graphene	High sensitivity and specificity in detection	Disease-specific biosensors for diabetes, cancer
Immunoassays	Magnetic nanoparticles, Quantum dots	Signal amplification, increased accuracy	Early detection of cancer, infectious diseases
Nucleic Acid-Based Detection	Silver nanoparticles, Carbon nanotubes	Improved amplification efficiency	Detection of genetic markers for early diagnosis
Imaging Techniques	Iron oxide nanoparticles, Gold nanoparticles	Enhanced contrast and resolution	Early detection of tumors, neurodegenerative diseases
Lab-on-a-Chip Devices	Graphene, Gold nanoparticles	Miniaturization, portability, rapid diagnostics	Point-of-care diagnostics, early disease detection

Table 4: Comparative Analysis of Nanomaterial-Based Analytical Methods

Analytical Method	Nanomaterial	Sensitivity	Specificity	Limit of Detection (LOD)	Time Required
Electrochemical Sensing	Graphene	High	High	10^-9 M	~5 minutes
Optical Sensing	Gold Nanoparticles	Very High	Moderate	10^-12 M	~10 minutes
Magnetic Resonance	Magnetic Nanoparticles	Moderate	High	10^-6 M	~30 minutes
Fluorescence Imaging	Quantum Dots	Very High	High	10^-15 M	~20 minutes

Advantages and Challenges

Advantages: Nanomaterial-based analytical techniques offer several advantages that make them highly valuable for early disease detection. Firstly, they provide enhanced sensitivity and specificity, allowing for detecting very low concentrations of biomarkers, which is crucial for identifying diseases at their earliest stages. Secondly, the miniaturization of devices enabled by nanomaterials paves the way for portable, point-of-care diagnostics, making healthcare more accessible, especially in remote or resource-limited areas. Additionally, nanomaterials allow for multiplexing capabilities, where multiple biomarkers can be detected simultaneously, increasing the efficiency and comprehensiveness of diagnostic tests [22-24].

Challenges: Despite their advantages, nanomaterial-based techniques face several challenges that must be addressed. Manufacturing and scalability are significant issues, as producing nanomaterials with consistent quality and in large quantities remains complex and costly. Biocompatibility and toxicity are also concerns, as the interaction of nanomaterials with biological systems can lead to unintended side effects, raising safety issues for clinical applications. Finally, regulatory and ethical considerations are critical, as introducing new nanomaterial-based diagnostics into the market requires stringent regulatory approval, and ethical concerns must be addressed regarding their use in healthcare, particularly regarding patient safety and privacy [25].

Table 5: Challenges and Future Directions in Nanomaterial-Based Diagnostic Methods

Challenge	Description	Potential Solution	Current Research Focus
Biocompatibility	Potential toxicity of nanomaterials	Surface modification with biocompatible polymers	Development of safer coatings
Stability	Nanomaterials prone to aggregation	Stabilisation through surfactants	Synthesis of more stable nanostructures
Cost	High cost of production	Scalable synthesis methods	Research on cost-effective production techniques
Regulatory Approval	Lack of standardise	Development of unified	Collaboration with

	d protocols	guidelines	regulatory bodies

Applications in Early Disease Diagnosis

Cancer: Nanomaterial-based methods have significantly advanced the early detection of various cancers by enabling the identification of tumour-specific biomarkers at very low concentrations. Techniques such as nanomaterial-enhanced biosensors and imaging modalities like nanoparticle-assisted MRI and PET scans allow for the early detection of cancers like breast, prostate, and lung cancer. Specific examples include gold nanoparticle-based assays for detecting prostate-specific antigen (PSA) and quantum dot-based imaging for visualising early-stage Tumors, which have shown promising results in clinical studies [26].

Cardiovascular Diseases: Early diagnosis of cardiovascular conditions, such as heart attacks and strokes, is greatly enhanced by nanomaterial-based detection of specific biomarkers like troponins and C-reactive protein (CRP). Nanoparticles improve the sensitivity of biosensors and assays, enabling the detection of these biomarkers at levels that indicate early stages of cardiovascular diseases, often before significant symptoms develop [27].

Infectious Diseases: Nanomaterials play a crucial role in rapidly and sensitively detecting viral, bacterial, and parasitic infections. Techniques such as nanoparticle-based immunoassays and nucleic acid amplification tests allow for the early detection of diseases like HIV, tuberculosis, and malaria. These methods offer faster results and higher sensitivity than traditional diagnostic techniques, making them particularly useful in outbreak and resource-limited settings [28].

Neurodegenerative Diseases: Nanomaterials are increasingly used in the early diagnosis of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. For example, nanoparticle-based imaging agents can cross the blood-brain barrier and detect early pathological changes associated with these diseases. Additionally, nanomaterial-enhanced biosensors can identify early biomarkers in cerebrospinal fluid or blood, potentially enabling diagnosis before significant neurodegeneration occurs [29].

Diabetes and Metabolic Disorders: In the context of diabetes and metabolic syndrome, nanomaterials detect early biomarkers such as glucose, insulin, and adipokines. Nanoparticle-based glucose sensors, for instance, provide highly sensitive and continuous monitoring of blood sugar levels, facilitating early diagnosis and better diabetes management. Similarly, nanomaterial-enhanced assays can detect early signs of metabolic disorders, allowing timely intervention [30-33].

Table 6: Examples of Commercialized Nanomaterial-Based Diagnostic Tools

Product Name	Company	Nanomaterial Used	Target Disease	Market Availability	Clinical Utility
Verigene®	Luminex Corporation	Gold Nanoparticles	Bacterial Infections	Yes	Rapid pathogen identification
Epi proLung®	Epigenomics AG	Magnetic Nanoparticles	Lung Cancer	Yes	Early cancer detection
T2Bacteria®	T2 Biosystems	Magnetic Nanoparticles	Sepsis	Yes	Fast sepsis diagnostics
NanomixeLab®	Nanomix	Carbon Nanotubes	Cardiac Markers	Yes	Portable diagnostic device

Future Prospects

Innovations on the Horizon: Emerging nanomaterials, such as two-dimensional materials (e.g., graphene derivatives) and novel hybrid nanoparticles, are showing great promise in disease diagnosis. These materials offer enhanced properties, such as improved biocompatibility, higher sensitivity, and multifunctionality, which could lead to even more effective diagnostic tools. Additionally, advancements in nanofabrication techniques, such as 3D printing and nano-lithography, are making it possible to produce highly precise and scalable nanomaterials, which can significantly improve the quality and accessibility of nanomaterial-based diagnostics.

Integration with Other Technologies: The future of diagnostics lies in the integration of nanomaterials with advanced technologies like artificial intelligence (AI), machine learning, and big data analytics. This combination can enhance the analysis of complex diagnostic data, allowing for more accurate and faster disease detection. Moreover, it opens the door to personalized medicine, where diagnostic tools can be tailored to the individual's genetic makeup and disease risk profile, leading to precision diagnostics that offer customized treatment options and better outcomes.

Clinical Translation and Commercialization: Bringing nanomaterial-based diagnostics from the lab to the clinic involves overcoming several challenges, including regulatory approval, manufacturing scalability, and ensuring safety and efficacy in clinical settings. However, pathways to commercialization are paved by successful case studies where nanomaterial-based diagnostics have already reached the market. Examples include nanoparticle-based blood tests for cancer detection and quantum dot-based imaging agents. Ongoing clinical trials are further validating these technologies, and as more success stories emerge, the widespread adoption of nanomaterial-based diagnostics in clinical practice is becoming increasingly likely [34-38].

Conclusion

Nanomaterials have revolutionized the field of early disease diagnosis by providing unprecedented sensitivity and specificity in various analytical methods. These advanced materials enable the detection of disease biomarkers at much lower concentrations than traditional diagnostic techniques, which is critical for identifying diseases at their earliest stages. Nanomaterial-based diagnostic methods, including biosensors, immunoassays, and molecular imaging, pave the way for more accurate and rapid diagnosis, particularly in resource-limited settings. However, challenges such as manufacturing scalability, biocompatibility, and regulatory approval must be addressed to facilitate the broader clinical adoption of these technologies. As research in this field progresses, integrating nanomaterials with cutting-edge technologies like artificial intelligence and big data analytics will enhance diagnostic capabilities further, leading to more personalized and precise healthcare solutions. The ongoing development of novel nanomaterials and the successful commercialization of nanomaterial-based diagnostic tools underscore the transformative potential of these technologies in improving patient outcomes and reducing healthcare costs. The evolution of nanomaterial-based diagnostics will undoubtedly play a crucial role in advancing early disease detection and treatment.

Funding
No Funding

Acknowledgement
Not Declared.

Conflict of Interest
No Conflict of interest.

Informed Consent
Not applicable.

Ethical Statement
Not applicable.

Author Contribution
Not Applicable.

References
1. Kumar A, Sharma K, Dhanjal DS, Nepovimova E, Kuča K, Singh R. Recent advances in nanotechnology for the treatment of Alzheimer's disease: A comprehensive review. J Adv Res. 2020;19:15-29.
2. Wang Y, Yan X, Wang S, Song J, Li B. Nanomaterial-based biosensors for environmental pollutant detection and cleanup. Environ Sci Nano. 2019;6(3):754-77.
3. Zhang Y, Yu J, Bomba HN, Zhu Y, Gu Z. Mechanochemically responsive materials for on-demand drug delivery. AccChem Res. 2019;52(2):361-72.
4. Li Y, Li X, Dong X, He X, Zhang C, Li H, et al. Recent advances in nanomaterial-based biosensors for detection of exosomes. Anal Bioanal Chem. 2020;412(26):7673-83.
5. Niroja Vadagam, Sharath Babu Haridasyam, MuvvalaVenkatanarayana, Narasimha S. Lakka, Sanjeeva R. Chinnakadoori, Separation and quantitative estimation of stereo-selective enantiomers of montelukast in pharmaceutical drug substance and tablets dosage forms by using stability-indicating normal phase-HPLC method, Chirality, 2023, 35(12), 952-965
6. Lim SY, Shen W, Gao Z. Carbon quantum dots and their applications. ChemSoc Rev. 2015;44(1):362-81.
7. Mohan Pasham, Sharath Babu Haridasyam, Niroja Vadagam, NVVD Praveen Boppy, Sanjeeva R Chinnakadoori, Narasimha S Lakka, Separation and quantification of organic-related impurities of betaadrenergic receptor blocking agent propranolol in pharmaceutical solid dosage forms: Impurity profiling using stability-indicating HPLC method, 2024, 7(1), 2300159.
8. Ray PC, Yu H, Fu PP. Toxicity and environmental risks of nanomaterials: Challenges and future needs. J Environ Sci Health C Environ CarcinogEcotoxicol Rev. 2009;27(1):1-35.
9. Zhu X, Zhang J, Zhang Y, Ye H, Liu J. Recent progress in carbon quantum dots: Synthesis, properties and applications in photocatalysis, sensing, and bioimaging. J Mater Chem C. 2021;9(28):9070-110.
10. Jagtap RV, Jyoti MA, Kumar AR, Shaikh SA, Debnath M, Kumar S, et al. Recent advances in carbon quantum dots as sensing materials for detection of environmental pollutants. Mater Today Proc. 2020;26:2442-47.
11. Huang X, Aguilar ZP, Xu H, Lai W, Xiong Y. Nanomaterial-based biosensors for detection of foodborne pathogens and toxins. Trends Analyt Chem. 2016;85:139-50.
12. Khan M, Hasan M, Hossain MI, Haque E, Uddin MJ, Islam MT. Recent advances in nanomaterial-based biosensors for cancer biomarkers detection. Biomaterials. 2021;266:120-23.
13. Papinaboina Venkata Rao, Chinnakadoori Sanjeeva Reddy, Ravi Kumar Marram, DantuDurga Rao, Simultaneous Determination Of Omeprazole And Domperidone In Capsules And In Vitro Dissolution Studies By Using Stability Indicating UPLC, Journal of liquid chromatography & related technologies, 2012, 35 (16), 2322-2332.
14. Narasimha S Lakka, Chandrasekar Kuppan, Niroja Vadagam, Poornima Ravinathan, KalyaniChepuri, Sanjeeva R Chinnakadoori, Molecular docking, in-vitro anticancer evaluation and ADME profiling of 7-Oxo Midostaurin, Journal of Molecular Structure, 2023, 1293, 136159.
15. Niroja Vadagam, Sharath Babu Haridasyam, MuvvalaVenkatanarayana, Narasimha S Lakka, Sanjeeva R Chinnakadoori, Separation and simultaneous estimation of enantiomers and Diastereomers of muscarinic receptor antagonist Solifenacin using stability-indicating Normal-phase HPLC technique with chiral stationary phase amylose tris-(3,5-dimethylphenylcarbamate), Chirality, 2024, 36(2), e23632.
16. N. V. V. D. Praveen Boppy, Sharath Babu Haridasyam, Niroja Vadagam, MuvvalaVenkatanarayana, Sanjeeva R. Chinnakadoori, Narasimha S. Lakka, Separation and quantification of organicrelated impurities of anti-histamine drug hydroxyzine in pharmaceutical dosage forms using stability-indicating high-performance liquid chromatography, liquid chromatography-mass spectrometry, and high-resolution mass spectrometry techniques, Separation Science Plus, 2024, 2300157.
17. Tiwari JN, Tiwari RN, Kim KS. Zero-dimensional, one-dimensional, two-dimensional and three-dimensional

nanostructured materials for advanced electrochemical energy devices. Prog Mater Sci. 2012;57(4):724-803.
18. Sharma S, Hussain S, Bora MB, Deka S, Bhattacharjee S, Pathak K, et al. Recent advances in microfluidic biosensors for point-of-care diagnostics. Anal Methods. 2020;12(10):1030-44.
19. Niroja Vadagam, Sharath Babu Haridasyam, MuvvalaVenkatanarayana, Narasimha S Lakka, Sanjeeva R Chinnakadoori, Separation and quantitation of valacyclovir enantiomers using stability-indicating chiral liquid chromatography method with a chiral stationary phase of amylose tris-(3,5-dimethyl phenyl carbamate), Separation Science Plus, 2023, 6(12), 2300145.
20. Manda P, Popescu C, Juluri A, Janga K, Kakulamarri PR, Narishetty S, et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. AAPS PharmSciTech. 2018 Jan 19;19(3):1358–66.
21. Lee J, Kim J, Kim S, Min DH. Biosensors based on graphene oxide and its biomedical application. Adv Drug Deliv Rev. 2016;105:275-87.
22. Chen A, Chatterjee S. Nanomaterials based electrochemical sensors for biomedical applications. ChemSoc Rev. 2013;42(12):5425-38.
23. Kakulamarri PR, Latha Alikatte K. Transdermal Iontophoresis of Non-Polar Drugs: A Mini Review. Journal of Pharmaceutics & Drug Delivery Research. 2016;5(3).
24. Sajid M, Kawde AN, Daud M. Designs, formats and applications of lateral flow assay: A literature review. J Saudi Chem Soc. 2015;19(6):689-705.
25. Dhawan A, Sharma V, Parmar D. Nanomaterials: A challenge for toxicologists. Nanotoxicology. 2009;3(1):1-9.
26. Umer A, Naveed M, Ramzan N, Rafique MS, Imran M. A green method for the synthesis of copper nanoparticles using L-ascorbic acid. Mater Today Proc. 2015;2(6):4278-82.
27. Lakshmi Narasimha Rao K, Praneeth Rao K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. Chromatographia. 2017 Jun 23;80(8):1211–24.
28. Choi M, Kang C, Lee S, Kim SH, Hwang DW, Lee D, et al. Surface modified carbon nanotubes for intracellular delivery of therapeutic molecules. J Mater Chem. 2021;9(25):14345-53.
29. Huo J, Wen X, Wang N, Zhang Y, Shi Z. Nanomaterial-based biosensors: Promising tools for rapid detection of COVID-19. J Nanobiotechnology. 2021;19(1):1-21.
30. Rao Kakullamarri P, Tiyyagura P, Suresh Babu K. A Stable Formulation of a Non-Steroidal Anti-inflammatory Drug, Ibuprofen and an Antihistamine drug, Famotidine for a Combination Therapy. Journal of International Research in Medical and Pharmaceutical Sciences. 2023 Nov 1;18(2):38–50.
31. Yang J, Li X, Xu J, Wang Y. Recent advances in nanomaterial-based biosensors for detection of pathogens. Bioengineered. 2021;12(1):7448-63.
32. Al-Ogaidi I, Gou H, Al-Kazaz AK, de la Chapelle ML, Al-Khaled K, McLandsborough L, et al. A nanomaterial-based optical biosensor for rapid and sensitive detection of foodborne pathogens. BiosensBioelectron. 2017;96:373-79.
33. Wang S, Xu L, Zhang X, Wang L, Xiao Y. Recent advancements in nanomaterial-based biosensors for the detection of marine toxins. TrAC Trends Anal Chem. 2021;144:116-38.
34. Kakullamarri PR, Rao KLN (2017) Enhanced Bioavailability and Anticancer Activity of Vitamin Analogs. J BioequivAvailab 9: 439-441
35. Tang D, Liu B, Niessner R, Knopp D. Nanoparticle-based immunosensors in environmental analysis. TrAC Trends Anal Chem. 2011;30(8):1138-49.
36. Malik P, Katyal V, Malik V, Asatkar A, Inwati G, Mukherjee TK. Nanobiosensors: Concepts and variations. ISRN Nanomaterials. 2013;2013:1-9.
37. Ren Y, Zhou Z, Wu H, Guo X, Song Y, Zhang Y. Recent advances in nanomaterial-based biosensors for antibiotics detection. BiosensBioelectron. 2019;142:1-14.
38. Li X, Li P, Zhang Z, Chi Q. Nanomaterial-based biosensors for environmental monitoring. Curr Opin Environ Sci Health. 2020;16:62-70.